Workflow
天坛生物2025年上半年营收实现31.10亿元

Core Insights - Tian Tan Biological Products Co., Ltd. reported a revenue of 3.11 billion yuan for the first half of 2025, representing a year-on-year increase of 9.47%, while the net profit attributable to shareholders decreased by 12.88% to 633 million yuan [1] - The decline in net profit was attributed to a decrease in product sales prices compared to the previous year and reduced interest income due to changes in credit policies [1] Financial Performance - Revenue for the second quarter of 2025 reached 1.793 billion yuan, a quarter-on-quarter increase of 36.04% [1] - Net profit for the second quarter was 388 million yuan, reflecting a quarter-on-quarter increase of 59.09% [1] Business Operations - The company focuses on the research, production, and sales of blood products, including human albumin, intravenous immunoglobulin, and tetanus immunoglobulin [1] - Tian Tan Biological is actively expanding its market presence, enhancing blood source development, and accelerating product delivery processes [1] Research and Development - The company maintains a high level of investment in research and development, having obtained 2 authorized patents during the reporting period, including 1 invention patent and 1 utility model patent [2] - Efforts are being made to promote engineering projects and information technology construction, facilitating intelligent upgrades and industrial collaboration [2] International Strategy - Tian Tan Biological is implementing an international strategy, focusing on the development and registration of products in overseas markets [2] - The company is engaged in compiling product registration materials and initiating application processes for multiple target markets [2]